Comparative Pharmacology
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 200.
HEXABRIX vs ISOVUE-200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
Intravenous: 0.3-0.6 mL/kg (maximum 100 mL) for urography; 40-80 mL for CT enhancement.
Intravenous administration of 1.0-2.0 mL/kg (200 mg iodine/mL) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 mL total. Maximum recommended dose: 2.0 mL/kg.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance.
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination.
Category C
Category C
Contrast Media
Contrast Media